Intra-Aortic Balloon Pump Therapy
The predominant MCS device -
a trusted, valuable first-line option
IABP Therapy has been around for over 50 years.
IABP has been the first line choice for mechanical circulatory support due to its clinical efficacy, safety profile and low cost. It has been and continues to be the most widely used Mechanical Circulatory Support (MCS) device.
If you are a current user of our IAB and IABP devices, please click on the link below to find the latest product support and software update information.
The Science Behind IABP Therapy
Rationale and Best Practices for IABP: What's the Data for Specific Indications?
SCAI clinical expert consensus statement on the classification of cardiogenic shock
A multidisciplinary group of experts convened by the Society for Cardiovascular Angiography and Interventions was assembled to derive a proposed classification schema for cardiogenic shock.
Influence of intra-aortic balloon pump on mortality as a function of cardiogenic shock severity
IABP use was associated with substantially lower in-hospital mortality in patients with CS, without differences in this effect across the SCAI shock stages
IABP in non-ACS Cardiogenic Shock
The Role of Intra-Aortic Counterpulsation in Cardiogenic Shock Patients Without an Acute Coronary Syndrome: Can Early Placement of IABP Improve End Organ Perfusion and Lower Mortality and MACE?
Fiber-optic technology is a way to minimize the inaccuracies of a fluid-filled system. Combined with Getinge's larger volume balloon, patients receive greater systolic unloading, higher augmentation with the potential of a greater increase in cardiac output than the older 40cc balloons.
Large Volume Balloons
IABC using a larger volume 50cc balloon appears effective as a first line percutaneous MCS strategy in a large fraction of critically ill cardiac patients with few adverse events. An IABP first approach was associated with fewer significant complications when using large volume IABs which displace more blood in the aorta during diastole, resulting in improved augmentation and unloading compared to large bore catheters.
Patients with CS who were selected to receive an IABP had lower in-hospital mortality, without differences in this effect across the SCAI shock stages. 
Early use of IABP in CS was associated with significant improvement in 30-day mortality regardless of the etiology of Cardiogenic Shock. 
Primary circulatory support by IABP showed a significant increase in improved organ perfusion assessed by SvO2. 
A subset of chronic systolic HF patients had robust hemodynamic response to IABP with significant CO augmentation and MPAP reduction.